No Data
No Data
Analysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Galmed Pharmaceuticals (GLMD) and Xilio Therapeutics (XLO)
Galmed Pharmaceuticals Shares Are Trading Higher After the Company Announced Results From Its First Set of Oncology Studies.
Galmed Pharma: First Set Of Oncology Studies Show Aramchol Enhances Liver / Colorectal Cancer-approved Therapeutic Regorafenib Effects In Liver And Colon Cancers In-vitro And In-vivo Models
Express News | Galmed Pharmaceuticals Ltd - Phase 1B Study of Aramchol and Regorafenib to Start Q4 2025
Express News | Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in Gi Cancer Models
Analysts Conflicted on These Healthcare Names: Galmed Pharmaceuticals (GLMD) and Regeneron (REGN)